In the DIO mouse model, the DPP-4 inhibitor sitagliptin significantly improved the metabolic disorder exacerbated by niacin, including impaired glucose metabolism, abnormal islet morphology and decreased β cell mass. Here, DPP4 is linked to metabolic disease.